Amgen Inc. has completed the acquisition of the privately held biopharmaceutical company Avidia. The Mountain View, Calif.-based company’s lead product candidate is a treatment for inflammation and autoimmune diseases in phase one clinical trials. The deal was announced in late September. Amgen is based in Thousand Oaks.